Ephrata PUD office receiving ADA upgrades, closed until March 21
Mar. 13—EPHRATA — The Grant County Public Utility District headquarters building, 30 C St. SW in Ephrata, will be closed from March 10 to March 21 to install accessibility upgrades and refurbish some of the public areas, according to PUD public information officer Christine Pratt. The upgrades will cost the utility district around $32,500.
"Basically, the idea is to lower part of the counter, so it makes it more wheelchair friendly," Pratt said. "That counter is attended by customer service representatives. There are humans there to help out. The lower counter is just in case a customer in a wheelchair wants to come in and pay their bill in person, or if they have to come in to do any business and they maybe have to sign something. It's just going to be at a height that makes it more comfortable for them to do that."
Pratt said customers in wheelchairs have been able to access the counter, but it was too tall for them to do so comfortably. The upgrade is just to ensure all customers are accommodated and can receive the assistance they need.
"We've just managed to work around it," Pratt said. "I mean, the customer service representatives are pretty accommodating. Anybody who comes in gets on the same level of service. It's just that this is something that the law requires that we're doing now."
Outside of the ADA upgrade, the building will also be getting new furniture and will be touched up since it hasn't been upgraded since it was built, according to Pratt.
"Then they're also going to just kind of freshen the area up because it's been a long time, 15 or 20 years since all of that was built," Pratt said. "They're just going to kind of (refurbish it) and add some new furniture and stuff to the area. But the main reason that it's closed is for ADA improvements."
The Moses Lake office will remain open at 312 W. Third Ave. for customers who need in-person assistance. The PUD's customer service line will still be open at 509-766-2505 if customers need to talk to a person about their bill or any other topic. Customers can also visit GrantPud.org to pay their bills and have questions answered.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Walton County to break ground on Driftwood Road
WALTON COUNTY, Fla. (WMBB) – The Walton County Board of County Commissioners and the Walton County Beach Operations and Tourism Departments plan to break ground on the Driftwood Road Municipal Parking facility. According to a news release, the construction will begin Monday, June 16, on 76 Driftwood Road in Miramar Beach at 9 a.m. U.S. 231 Road Improvement Project to begin in Bay County Walton County's need for public beach access, rest areas and transit stops led to the project approval from the BCC. The Driftwood Road Municipal Parking facility will include 67 parking spaces with dedicated ADA, LSV and bicycle parking. Four of the parking spots will also include electric vehicle charging stations. Officials say the construction of the 1.119-acre lot will take approximately 11 months. For visitors, the public transit stop will have air-conditioning as well as a restroom facility for convenience. The Tourist Development Tax, a 5% tax collected on short-term rentals in south Walton County, funds this development. For more information and project updates, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
10 hours ago
- Yahoo
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL. Presentation details: Symposium Title: Joint ADA/IPITA Symposium: Outpacing the Immune System—Sprinting Towards Immune Protection for Cell Replacement Therapy Presentation Title: Hypoimmune Pancreatic Islet Transplantation in Adult Subjects with Type 1 Diabetes Presentation Date: Monday, June 23, 2025 Presentation Time: 9:00 – 9:20 a.m. CT Location: W192 A-C About Sana Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA and Bothell, WA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the company's vision and expectations regarding participation in and the presentation at the 85th Annual American Diabetes Association Scientific Sessions, including the content of such presentation. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's Securities and Exchange Commission reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. Investor Relations & Media:Nicole
Yahoo
12 hours ago
- Yahoo
Nasdaq confirms XRP, SOL, ADA, and XLM in benchmark index via new SEC filing
Nasdaq confirms XRP, SOL, ADA, and XLM in benchmark index via new SEC filing originally appeared on TheStreet. Nasdaq has officially filed an SEC Form 8-K for the Hashdex Nasdaq Crypto Index US ETF, confirming it has reconstituted its benchmark index to include four new digital assets: Cardano (ADA), Solana (SOL), Stellar Lumens (XLM), and XRP. These coins are now part of the Nasdaq Crypto US Settlement Price Index (NCIUS), which the ETF uses as its benchmark. According to the filing dated June 2, this update marks a significant step toward broader crypto representation in institutional investment products. However, despite the change, the Trust will continue to hold only Bitcoin and Ethereum for now, due to its existing listing restrictions. 'Notwithstanding the changes to the NCI US, the Trust will continue to hold only BTC and ETH… due to the limitations of the Trust's currently approved listing rule,' the filing states. The update was disclosed in a Form 8-K, a standard filing companies use to inform investors of major events that shareholders should know about. In this case, it included the resignation of a key executive, as well as a major index reconstitution that may affect fund tracking performance. The filing warns of tracking error risk, noting: 'Beginning on June 2, 2025, the Index introduced additional Index Constituents… Under current regulatory restrictions, the Trust is only permitted to hold bitcoin and ether… As a result, the Trust's performance may be materially different from the performance of the Index.' Nasdaq has also filed a proposed rule change (SR-NASDAQ-2025-009) with the SEC that would allow the ETF to formally change its benchmark to the broader Nasdaq Crypto Index™ (NCI), enabling it to hold all nine listed crypto assets including LINK, LTC, and UNI. A decision on that proposal is expected by November 2, 2025. Nasdaq confirms XRP, SOL, ADA, and XLM in benchmark index via new SEC filing first appeared on TheStreet on Jun 9, 2025 This story was originally reported by TheStreet on Jun 9, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
